English   Chinese / 中文



How we see acquisitions in the Healthcare sector in China

As China’s pharmaceutical and medical device players are starting to show scale, they are bound to consolidate. Recently, the majority of China’s deal activity was related to drug manufacturing assets and drug commercialization, which is different to several years ago when CRO services were the name of the game. Many local players have reshuffled their investment portfolios and acquired other domestic companies, driving the consolidation forward in terms of production capacities as well as sales & distribution channels. On the other hand, foreign pharma players realized that China has become the world’s second largest drug market that keeps growing at 15 – 18% p.a., and they keep trying to find a fast entry or expansion in the Chinese market via M&A. In the medical device sector, larger foreign players have started to acquire the domestic top players (as very evident in orthopedics), not the least to bridge registration issues of their import portfolios. With a domestic market continuing to grow at fast speed, deal valuations will remain higher compared to other industries in the years to come.

Our qualifications in the Healthcare sector

Since 2008, InterChina features a specialist group dedicated to advise on transactions in the healthcare space. The group focuses on the healthcare sector exclusively, and features professionals with life sciences / pharma / medical devices background, which is sensitive to the very nature of transactions in the healthcare space. We commonly work on inbound buy-side mandates for international clients, but increasingly on restructuring and sell-side, as well as outbound buy-side mandates for Chinese clients. Our team handles both pharma as well as medical device-related mandates, and our mandates range from in-/out-licensing deals over to co-marketing / alliance deals to full-blown company acquisitions.

Why our capabilities are relevant in the Healthcare sector

Our proactive and systematic approach to originate targets and deal opportunities has proven to be superior to opportunistic approaches, especially in spaces where the largest available partners are often State-owned companies and not always suited to fulfill strategic objectives. Our dedication and specialization in the healthcare space allows us to engage with clients on a strategic level, bringing a contextual understanding to complex and shifting transaction issues, and advising on acquisition strategy and options. Furthermore, transactions in the healthcare space bring additional complexities, and require a holistic understanding and approach to navigate and manage potential deal breakers the right way.

  PDF Download | EN

A summary of typical clients provided below.

Typical Clients


  • API
  • CRO
  • CSO
  • TCM
  • Generics
  • Innovative
  • Biopharma
  • Intermediates

Medical Devices

  • IVD
  • Dental
  • Implants
  • Diagnostics
  • Orthopedics
  • Wound Care
  • Capital Goods
  • Consumables

Services & Supplies

  • Hospitals
  • Home Care
  • Clinic Chains
  • Ambulances
  • Hospital Supplies
  • Hospital Care Beds
  • Clinical IT Systems
  • Service Providers To Clinics

Tefen Management Consulting

InterChina has partnered with Tefen Management Consulting to deliver our clients an expanded service portfolio that now includes Manufacturing & Quality, Operation & Organization and Supply Chain projects.

Tefen is an international management consulting firm with branches in the USA, Israel, India and across Europe. Tefen specializes in Life Science and Healthcare operational consulting, and they are known to be extremely hands-on and results-oriented.

Together with InterChina's extensive China market expertise, our clients in the Life Sciences and Healthcare sectors will find all of their China market needs covered.

Find out more about Tefen: http://www.tefen.com